- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00627744
Beta-cell Function in Glucose Abnormalities and Acute Myocardial Infarction (BEGAMI)
Phase IV Study Evaluating the Effect of Sitagliptin (Januvia™) on Beta-cell Function in Patients With Acute Myocardial Infarction or Unstable Angina Pectoris and Newly Detected Impaired Glucose Tolerance or Type 2 Diabetes.
A three months, double-blind, randomised, parallel-group study evaluating the efficacy of sitagliptin (Januvia™) versus placebo on beta-cell function in patients with newly detected glucose abnormalities and acute myocardial infarction or unstable angina pectoris.
Primary endpoint Improvement in beta-cell function measured by means of the insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT).
Secondary endpoints
- Improvement of glucose tolerance by means of an OGTT
- Improvement in endothelial function
- Improvement in incretin-independent beta-cell function measured as the Acute Insulin Response (ΔAIRG) during an intravenous glucose tolerance test
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
GENERAL AIM / PRIMARY OBJECTIVE The primary objective is to show that sitagliptin (Januvia™) 100 mg once daily for three months improves beta-cell function in patients with AMI or unstable angina pectoris and newly discovered glucose abnormalities (IGT or T2DM).
PRIMARY ENDPOINT The primary endpoint is improvement in beta-cell function after three months treatment measured by means of insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT).
SECONDARY ENDPOINTS
- Improvement of glucose tolerance tested with an OGTT after three months.
- Improvement in endothelial function (measured with Endo-PAT2000, Itamar) after three months.
- Improvement in GLP-1 independent beta-cell function after three months measured as the ΔAIRG obtained from a "Frequently sampled intravenous glucose tolerance test" (FSIGT).
NUMBER OF PATIENTS PLANNED A total of 70-80 consecutive patients will be included with 35-40 patients in each treatment arm.
TREATMENTS TO BE COMPARED Active substance: Sitagliptin Januvia™ 100 mg once daily orally during three months
Comparator drug Placebo
CONCOMITANT THERAPY All patients should receive evidence based treatment for secondary prevention of coronary heart disease according to the most recent ESC guidelines [60,61].
All patients will receive structured life style intervention strategies according to local practise.
EFFICACY The primary endpoint is improvement in beta-cell function after three months treatment measured by means of insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT).
Secondary endpoints
- Improvement of glucose tolerance tested with an OGTT after three months.
- Improvement in endothelial function (measured with Endo-PAT2000, Itamar) after three months.
- Improvement in GLP-1 independent beta-cell function after three months measured as the ΔAIRG obtained from a "Frequently sampled intravenous glucose tolerance test" (FSIGT).
Methodology OGTT: Oral administration of 75 g of Glucose in 200 ml water with lemon extract is administered on the morning following an overnight fast of 12 hours A capillary blood glucose curve is obtained during 2 hours (just before and at 30, 60, 90 and 120 minutes after the glucose ingestion).
Endo-PAT2000: The Endo-PAT2000 is a non-invasive device for non-invasive characterisation of endothelial function and dysfunction and arterial stiffness. The endothelial function assessment is based on the endothelial mediated arterial response (at the level of a distal phalanx of a finger) to a five-minute occlusion of the brachial artery.
FSIGT: The patient is investigated on the morning after an overnight fast. A catheter will be inserted into an antecubital vein for blood sampling and into a contralateral antecubital vein for glucose injection. Basal samples will be drawn at 10 and at 1 min. At time 0, glucose (300 mg/kg) will be injected during 1 min, and then additional samples will be collected at 3, 4, 5, 6, 8, 10, 15, 20, 25, 30, 40, 60, 80, 100, 120, 150, and 180 min [62].
INVESTIGATIONAL PLAN This is a three months, double-blind, randomised, parallel-group study evaluating the efficacy of sitagliptin (Januvia™) versus placebo on beta-cell function in patients with AMI or unstable angina pectoris with newly discovered glucose abnormalities (IGT + T2DM).
SAMPLE SIZE ISSUES The assumption for the sample size calculation is based on a previous study from our group where the insulinogenic index was measured in patients with AMI and newly discovered type 2 diabetes and IGT [21]. The mean and standard-deviation of the ΔAIRG are estimated to 50 ± 35 (pmol/mmol). To detect an increase of 50 % between the two treatment groups at a 5 % level of significance with 80 % power using a two-tailed t-test, a sample size of 64 patient would be necessary (PROC POWER in SAS 9.1.3). With an an additional 5 % to be able to use non-parametric methods the total sample size is set to 70 patients.
ETHICS AND REGULATORY The trial will not be initiated until the protocol and informed consent and subject information form have been reviewed and received approval from the local ethics committee.
Informed Consent and Subject Information Each patient should receive oral and written information. Patients will be included following oral and written consent. Patient data will be protected and patients will be insured by Swedish law. All patients must be informed that they, whenever they wish, may withdraw from the study and that they in case of withdrawal will be treated according to the best possible routine standards of the centre.
QUALITY ASSURANCE AUDIT Monitoring visits will be performed before inclusion of first subject, regularly during trial conduct and after data based closed in collaboration with the Karolinska Clinical Research Trial and Support Centre. The investigators will permit trial-related monitoring, audits, IRB/IEC reviews, and regulatory inspections, providing direct access to source data/documents.
ADVERSE EVENTS All adverse events, serious and non-serious, occurring during the course of the clinical trial will be collected, documented and reported to the sponsor by the investigator. An adverse event is defined as any untoward medical occurrence in a clinical investigation subject administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.
The non-serious adverse events that have been observed in patients treated with sitagliptin are (>5% incidence and greater incidence than placebo):
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Stockholm, Sweden
- Karolinska University Hospital Solna
-
Stockholm, Sweden, 171 76
- Karolinska Institutet
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients diagnosed with an acute myocardial infarction or unstable angina pectoris according to the joint ESC and ACC recommendations [58].
- Classification of impaired glucose tolerance (IGT) or type 2 diabetes (T2DM) by means of an oral glucose tolerance test (OGTT) according to WHO [59].
- Patients who have signed a written informed consent consistent with ICH-GCP guidelines and local legislations prior to participation in the trial.
Exclusion criteria:
- No informed consent.
- <18 years old.
- Previous known type 2 diabetes.
- Admission plasma glucose >12 mmol/L.
- Impaired renal function (S-creatinine ≥ 130 μmol/L or need of renal dialysis).
- BMI>30.
- Known Type 1 diabetes, GAD positive or C-peptide<0.30.
- Patients with severe concomitant disease (i.e. malignancy, liver failure).
- Patients who at discharge are planned for Coronary Artery Bypass Grafting or percutaneous coronary intervention.
- Congestive heart failure (NYHA III-IV).
- Pregnant or nursing women or women of childbearing potential not using a medically approved means of contraception.
- Patients who, in the opinion of the investigator, will have difficulties to comply with the protocol (examples: alcohol or drug abuse, psychiatric disorder, resident outside of the catchment area).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: BE 1
Patients in this arm are randomly assigned to treatment with placebo
|
BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
Other Names:
|
Active Comparator: BE 2
Patients in this arm are randomly assigned to treatment with Sitagliptin
|
BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement in beta-cell function measured by means of the insulinogenic index (ΔI30/ΔG30) obtained from an oral glucose tolerance test (OGTT)
Time Frame: By the end of the study as stated
|
By the end of the study as stated
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Improvement of glucose tolerance by means of an OGTT
Time Frame: As stated for the study
|
As stated for the study
|
Improvement in endothelial function
Time Frame: As stated for the study
|
As stated for the study
|
Improvement in incretin-independent beta-cell function measured as the Acute Insulin Response (ΔAIRG) during an intravenous glucose tolerance test.
Time Frame: As stated for the study
|
As stated for the study
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Lars Rydén, Professor, Karolinska Institutet, Stockholm, Sweden
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Ischemia
- Pathologic Processes
- Necrosis
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Glucose Metabolism Disorders
- Metabolic Diseases
- Pain
- Neurologic Manifestations
- Hyperglycemia
- Chest Pain
- Myocardial Infarction
- Infarction
- Glucose Intolerance
- Angina Pectoris
- Angina, Unstable
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protease Inhibitors
- Incretins
- Dipeptidyl-Peptidase IV Inhibitors
- Sitagliptin Phosphate
Other Study ID Numbers
- BEGAMI
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Myocardial Infarction
-
Azienda ULSS 5 PolesanaUniversity of PadovaUnknownMyocardial Infarction, Acute | ST Segment Elevation Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Italy
-
University Medical Centre LjubljanaCompletedCardiac Arrest | Postresuscitation Syndrome | Myocardial Infarction (ST-Elevation Myocardial Infarction and Non-ST-Elevation Myocardial Infarction)Slovenia
-
Fundacio Privada Mon Clinic BarcelonaMiracor Medical SANot yet recruiting
-
Stiftung Institut fuer HerzinfarktforschungGlaxoSmithKline; University Hospital Muenster; Klinikum NürnbergCompletedMyocardial Infarction | ST-Elevation Myocardial Infarction | Non-ST-Elevation Myocardial InfarctionGermany
-
Population Health Research InstituteCanadian Institutes of Health Research (CIHR); Boston Scientific CorporationActive, not recruitingST Elevation Myocardial Infarction | Non ST Elevation Myocardial InfarctionCanada
-
Bispebjerg HospitalOdense University Hospital; Zealand University Hospital; Hvidovre University... and other collaboratorsRecruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial Infarction (nSTEMI)Denmark
-
Barts & The London NHS TrustUniversity College, London; Queen Mary University of LondonCompletedAcute Myocardial InfarctionSwitzerland, Denmark, United Kingdom
-
University of LeedsUniversity College, LondonCompletedST-elevation Myocardial Infarction | Non ST-elevation Myocardial Infarction
-
Karolinska InstitutetUppsala University; The Swedish Research CouncilActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionSweden
-
Oslo University HospitalVestre Viken Hospital Trust; University of Oslo; University Hospital of North... and other collaboratorsActive, not recruitingST Elevation Myocardial Infarction | Acute Myocardial Infarction | Non-ST Elevation Myocardial InfarctionNorway
Clinical Trials on Sitagliptin
-
Merck Sharp & Dohme LLCCompleted
-
Emory UniversityMerck Sharp & Dohme LLCTerminated
-
Baylor College of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedType 1 DiabetesUnited States
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.CompletedType 2 Diabetes MellitusChina
-
University of Colorado, DenverMerck Sharp & Dohme LLCCompletedCardiovascular Disease | Type 2 DiabetesUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
University Hospital Inselspital, BerneFresenius KabiCompletedMalnourishment | Gastrointestinal TumorsSwitzerland
-
Beijing Chao Yang HospitalRecruiting
-
National Institute on Aging (NIA)Completed